NASDAQ:CRVO CervoMed Q2 2025 Earnings Report $3.15 -0.09 (-2.78%) As of 01:40 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast CervoMed EPS ResultsActual EPS-$0.70Consensus EPS -$0.57Beat/MissMissed by -$0.13One Year Ago EPSN/ACervoMed Revenue ResultsActual Revenue$1.76 millionExpected Revenue$1.45 millionBeat/MissBeat by +$315.00 thousandYoY Revenue GrowthN/ACervoMed Announcement DetailsQuarterQ2 2025Date8/8/2025TimeBefore Market OpensConference Call DateFriday, August 8, 2025Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) CervoMed Earnings HeadlinesCervoMed Inc. Reports Advancements in Neflamapimod Development for Dementia with Lewy Bodies and Announces Phase 3 Trial PlansMay 18 at 7:51 AM | quiverquant.comQCervoMed Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 18 at 7:30 AM | globenewswire.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 21 at 1:00 AM | Brownstone Research (Ad)CervoMed Insider Trading Activity | NASDAQ:CRVO | BenzingaMay 14, 2026 | benzinga.comCervoMed (CRVO) Gets a Buy from JonesTradingApril 27, 2026 | theglobeandmail.comCervoMed Highlights Neflamapimod Progress in Lewy Body DementiaApril 26, 2026 | theglobeandmail.comSee More CervoMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email. Email Address About CervoMedCervoMed (NASDAQ:CRVO), a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.View CervoMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingTarget Shows Strengths, But Analysts Want to See MoreFreight Boom: The Hormuz Blockade PaydayTJX Companies Fires on All Cylinders With 9% Revenue GrowthAnalog Devices Provides Much-Needed Pullback: How Low Can It Go?USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
